The approval marks the first time a new glass composition has been approved by FDA since the approval of borosilicate glass more than 100 years ago.
Corning, a NY-based technology company focused on specialty glass, ceramics, and related materials, announced that an unnamed, leading pharmaceutical manufacturer received FDA approval of its Corning Valor Glass to serve as primary packaging for a marketed drug product. The approval marks the first time a new glass composition has been approved by FDA since the approval of borosilicate glass more than 100 years ago.
According to an Oct. 25, 2019 press release, Valor Glass is designed with chemical durability, which improves resistance to breakage, damage, and particulate contamination. The stable design ensures increased throughput and quality assurance for pharmaceutical manufacturers.
“We are thrilled to reach this important milestone. This modernization of glass packaging was made possible through our strong customer relationships and our shared passion for life-changing innovations,” said Wendell P. Weeks, Corning’s chairman, CEO, and president, in the press release. “We would also like to recognize the members of [FDA’s] Emerging Technology Team. Their strong support encourages the development and adoption of innovative technologies like Valor Glass.”
“We believe that Valor Glass is the future of parenteral glass packaging for manufacturers. This FDA approval is an important first step on our journey to create a new standard in pharmaceutical glass packaging. It’s great news for patients, for the industry, and for Corning,” added Ronald Verkleeren, vice-president and general manager, Corning Pharmaceutical Technologies, in the press release.
Source:
